Fate Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that develops off-the-shelf, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, including multiplexed-engineered T-cell and natural killer (NK) cell product candidates incorporating novel synthetic controls of cell function for the treatment of cancer and autoimmune diseases; its pipeline features FT819 (CD19 CAR T-cell with FDA RMAT designation in systemic lupus erythematosus), FT522 (CD19/CD20 CAR NK cell), FT839 (next-generation CD19/CD38/CD20 CAR T-cell), FT836 (next-generation multi-antigen CAR T-cell targeting MICA/B/EGFR/HER2 for solid/hematologic malignancies and CD19/CD38/BCMA/GPRC5D for hematologic malignancies), and FT825 (HER2/EGFR CAR NK cell), among others in Phase 1 for indications such as systemic lupus erythematosus, systemic sclerosis, ANCA-associated vasculitis, idiopathic inflammatory myopathies, and solid tumors. Founded in 2007 and headquartered in San Diego, California, the company conducts research, development, clinical operations, and cGMP manufacturing from its facilities there, with operations focused on the United States and recent expansion of clinical trial sites to the EU and UK. Latest developments include FDA IND allowance and Phase 1 initiation for FT836 in solid tumors, MHRA and EMA authorization to open ex-US sites for FT819 autoimmune trials, promising Phase 1 data for FT819 demonstrating durable SLEDAI-2K score reductions with no dose-limiting toxicities or graft-versus-host disease, extension of its partnership with Ono Pharmaceutical, plans for a registrational study of FT819 in moderate-to-severe SLE and lupus nephritis in 2026 under RMAT discussions with the FDA, and a cash runway extended through fiscal 2027 supported by $249 million in cash, equivalents, and investments as of Q2 2025.
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
The $13 Million Company Teaching the Immune System to Hunt Cancer
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference